NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · ASRT · USD
Stock price, earnings
Quote as of Jun 15, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Assertio Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Assertio Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in pediatric patients. Initially incorporated as Assertio Therapeutics, Inc. in 1995, the organization rebranded to Assertio Holdings, Inc. in May 2020 and maintains its corporate headquarters in Lake Forest, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $32.18M+12.24% vs estimate |
| Q3 2024 | Nov 11, 2024 | -$0.45+34.78% vs estimate | $29.20M+1.16% vs estimate |
|---|
| Q2 2024 | Aug 7, 2024 | -$0.60-1,900.0% vs estimate | $31.13M+3.47% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $22.65.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$100.32+$0.22 (+0.22%)
Lantheus Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.32% below the high.
$73.16+$1.45 (+2.02%)
ANI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.45% below the high.
$26.93+$0.60 (+2.28%)
Amphastar Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.77% below the high.
$4.04-$0.19 (-4.49%)
Aquestive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.7% below the high.
$1.94-$0.07 (-3.48%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.55% below the high.
$0.56+$0.02 (+4.07%)
Citius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
